Novel Treatments & Drugs

FDA Approves Genetic-Based Cancer Treatment that Could Help Mesothelioma Patients

Correcting genes that allow cancerous tumors to grow is the basis behind gene therapy, a relatively new treatment that is largely in experimental stages. The initial goals of gene therapy were to address hereditary genetic disorders, but other factors such as the sun, smoking, chemical exposure, etc., can all damage[…]

Read More »

Phase III Clinical Trial for Nintedanib Discontinued After Yielding Negative Results

Disappointing results from the LUME-Phase III clinical trial regarding nintedanib is a setback for scientists and researchers who were hopeful they were on the brink of finding a new, first line treatment for those suffering from mesothelioma. Results from the Phase II clinical trial – published earlier this year –[…]

Read More »

Survival Improves in Mesothelioma Patients who Received an Electricity-Based Treatment

The success of a recent Phase II clinical trial in malignant pleural mesothelioma has scientists and researchers excited about the possibility of adding a new treatment that will not only improve survival, but also improve quality of life of the cancer patient. Tumor Treating Fields, which is a therapy that[…]

Read More »

New Surgical Technique Illuminates Previously Undetected Mesothelioma Tumors

In addition to chemotherapy, radiation therapy, and immunotherapy, those suffering from mesothelioma also have the option for surgery (if they are physically able). Surgery is one of the better options for mesothelioma patients because it can remove most if not all the cancer; however, often times since the cancer is[…]

Read More »

Potential Breakthrough in Immunotherapy after Nivolumab Study Results

Immunotherapy treatments have once again made headlines, revolutionizing modern medicine and the way we have come to understand cancer treatment. The latest study results published in the American Journal of Case Reports, focuses on Opdivo (nivolumab), a type of check point inhibitor designed to stop immune cells from attacking the[…]

Read More »

Nintedanib May Surpass Bevacizumab as a More Effective Chemotherapy Treatment for Mesothelioma

In 2016, scientists and researchers were excited to begin Phase II of the clinical trial involving treating patients with malignant pleural mesothelioma with Nintedanib, a triple angiokinase inhibitor designed to hinder protein kinases in cancer cells and stop cancer cells from growing their own blood vessels. The LUME-Meso Phase II[…]

Read More »

Immunotherapy – What Side Effects Can You Expect?

As the success of immunotherapy treatments in improving survival and symptom management for cancer patients have started to become known, those suffering from cancer such as mesothelioma and lung cancer may now be given options in terms of the best course of treatment. Immunotherapy works with the body’s own natural[…]

Read More »

ONCOS-102 Update: Mesothelioma Patients Responded after Phase II Clinical Trial

Advancement in mesothelioma treatments over the past decade has been relativity stagnant, according to Targovax  – a Norwegian immune-cology company dedicated to the study and research of immunotherapy treatments. However, those suffering from mesothelioma have hope, as continuing phases of clinical trials are showing positive results; the latest being ONCOS-12,[…]

Read More »

Aerosol Chemotherapy – Targeting Peritoneal Mesothelioma Through Pressurized Medicine

Peritoneal mesothelioma is an incredibly rare form of cancer that affects the peritoneum, or abdominal lining. It is not entirely understood how exposure to asbestos causes this type of cancer, but scientists and researchers theorize that ingested asbestos fibers work themselves into the peritoneal cavity, or if inhaled, are transported[…]

Read More »